No Clinically Significant Drug Interactions Between HIV PrEP and Diabetes/Weight Loss Medications
HIV pre-exposure prophylaxis (emtricitabine/tenofovir) does not have clinically significant drug interactions with semaglutide (Ozempic), metformin, or dapagliflozin, and these medications can be safely co-administered.
Pharmacologic Basis for Safety
The combination is safe based on the distinct metabolic pathways of these medications:
HIV PrEP Metabolism
- Emtricitabine and tenofovir are nucleoside/nucleotide reverse transcriptase inhibitors that undergo minimal hepatic metabolism 11
- Emtricitabine does not inhibit CYP enzymes (CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4) at concentrations up to 14-fold higher than therapeutic levels 1
- Emtricitabine does not inhibit glucuronidation pathways 1
- Primary elimination is renal, not hepatic 11
Diabetes/Weight Loss Medications
- Semaglutide (Ozempic): GLP-1 receptor agonist metabolized by proteolytic cleavage, not dependent on CYP enzymes
- Metformin: Excreted unchanged in urine without hepatic metabolism
- Dapagliflozin: SGLT2 inhibitor with minimal CYP-mediated metabolism
Evidence from Drug Interaction Studies
The FDA label for emtricitabine explicitly documents that no clinically significant interactions were observed when studied with multiple medications 1. The Taiwan HIV PrEP guidelines specifically note that emtricitabine has "minimal drug-drug interaction" and tenofovir's interactions are limited to competing with renal tubular secretion 2.
Clinical Monitoring Considerations
While no dose adjustments are needed, standard monitoring for PrEP remains important:
Renal Function Monitoring
- Baseline and quarterly creatinine clearance is recommended for all PrEP users 333
- This is particularly relevant since:
- Metformin requires dose adjustment with renal impairment
- Dapagliflozin is contraindicated with severe renal dysfunction
- Tenofovir can affect renal tubular secretion 2
Specific Monitoring Schedule
- Before PrEP initiation: Serum creatinine and estimated creatinine clearance 33
- At 1 month: Creatinine clearance (first quarterly visit) 3
- Every 3-6 months: For patients with or at risk for kidney injury 33
- Annually: For those without kidney risk factors 3
Important Caveats
Avoid Adefovir Co-administration
The only documented contraindication is adefovir should not be used with tenofovir due to risk of renal tubular necrosis 2. This is not relevant to your question but worth noting for completeness.
Tenofovir Formulation Considerations
If the patient has pre-existing renal dysfunction (CrCl 30-60 mL/min) or osteoporosis risk, consider tenofovir alafenamide (TAF) instead of tenofovir disoproxil fumarate (TDF) 33. This choice is independent of the diabetes medications but relevant for overall patient safety.
Weight Monitoring
Recent data suggests TAF-based PrEP may be associated with greater weight gain compared to TDF 4. For patients on semaglutide specifically for weight management, this is worth discussing but does not constitute a drug interaction.
Practical Prescribing Approach
- Prescribe all four medications together without dose adjustments
- Monitor renal function per standard PrEP protocols (more important given metformin/dapagliflozin use)
- Counsel patient that no timing separation between medications is needed
- Document baseline creatinine clearance before initiating PrEP
- Reassess renal function at 1 month, then every 3 months initially
The 2025 CDC guidelines emphasize that regimen selection should consider "drug interaction potential with concurrent medications" 55, but emtricitabine/tenofovir specifically has minimal interaction potential, making it ideal for patients on multiple chronic medications.